BioLineRx (BLRX) Shares Outstanding (Weighted Average) (2021 - 2025)

BioLineRx has reported Shares Outstanding (Weighted Average) over the past 5 years, most recently at $2.6 billion for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $2.6 billion for Q4 2025, up 6753.07% from a year ago — trailing twelve months through Dec 2025 was $2.6 billion (up 6753.07% YoY), and the annual figure for FY2025 was $2.6 billion, up 6753.07%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $2.6 billion at BioLineRx, up from $38.1 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for BLRX hit a ceiling of $2.6 billion in Q4 2025 and a floor of $38.1 million in Q4 2024.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $923.0 million (2022), compared with a mean of $1.1 billion.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): crashed 96.49% in 2024 and later soared 6753.07% in 2025.
  • BioLineRx's Shares Outstanding (Weighted Average) stood at $662.9 million in 2021, then surged by 39.22% to $923.0 million in 2022, then increased by 17.73% to $1.1 billion in 2023, then crashed by 96.49% to $38.1 million in 2024, then soared by 6753.07% to $2.6 billion in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $2.6 billion (Q4 2025), $38.1 million (Q4 2024), and $1.1 billion (Q4 2023) per Business Quant data.